Tom 14, Nr 6 (2019)
Sprawozdanie z konferencji / Sprawozdanie
Opublikowany online: 2019-12-31
Wyświetlenia strony
674
Wyświetlenia/pobrania artykułu
1062
Postępy farmakoterapii w prewencji chorób serca — skuteczne leki, nieskuteczne suplementy. Dane z ostatnich kongresów AHA i ACC
1
, 1
, 1
DOI: 10.5603/FC.2019.0117
Folia Cardiologica 2019;14(6):648-654.
Streszczenie
Brak
Słowa kluczowe: badania klinicznekwas eikozapentaenowywitamina D3kwasy omega 3
Referencje
- Bhatt DL, Steg PG, Miller M, et al. REDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019; 380(1): 11–22.
- Borow KM, Nelson JR, Mason RP. Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis. Atherosclerosis. 2015; 242(1): 357–366.
- Mason RP, Dawoud H, Jacob RF, et al. Eicosapentaenoic acid improves endothelial function and nitric oxide bioavailability in a manner that is enhanced in combination with a statin. Biomed Pharmacother. 2018; 103: 1231–1237.
- Bhatt DL, Steg PhG, Miller M, et al. REDUCE-IT Investigators. Effects of icosapent ethyl on total ischemic events: from REDUCE-IT. J Am Coll Cardiol. 2019; 73(22): 2791–2802.
- Block RC, Liu L, Herrington DM, et al. Predicting risk for incident heartfailure with omega-3 fatty acids: from MESA. JACC Heart Fail. 2019; 7(8): 651–661.
- Manson JE, Bassuk SS, Buring JE, et al. VITAL Research Group, VITAL Research Group, VITAL Research Group, VITAL Research Group. Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med. 2000; 343(1): 16–22.
- Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019; 380(4): 347–357.
- EMPA-HEART cardiolink-6 trial: a randomized trial evaluating the effect of empagliflozin on left ventricular structure, function and biomarkers in people with type 2 diabetes (T2D) and coronary heart disease. http://www.abstractsonline.com/pp8/#!/4682/presentation/59526 (12.04.2019).
- Velazquez EJ, Morrow DA, DeVore AD, et al. PIONEER-HF Investigators. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019; 380(6): 539–548.
- Intensive vs. standard ambulatory blood pressure lowering to lessen functional decline in the elderly — INFINITY. https://www.acc.org/latest-in-cardiology/clinical-trials/2019/03/16/23/49/infinity (11.08.2019).
